The role of AI in drug discovery and delivery stands at a pivotal juncture. The integration of advanced computational approaches is not just an emerging trend but a fundamental shift in how we approach the creation of new therapeutics.

My guest for this week’s episode is Chris, Co-Founder & Product Lead at Nanograb, a YC biotech company (YC S23) that uses AI to generate the best combination of binders to treat different diseases.

Prior to co-founding Nanograb, Chris had a career in HSBC Hong Kong. Chris has a master degree in Biomaterials and Tissue Engineering at Imperial College London. His experience across biotech, finance and entrepreneurship give his unique insights you won’t want to miss.

-

Join us this episode to hear about:

• 00:59 Chris’ early upbringing and connection with his entrepreneurial drive


• 07:38 Chris’ gravitation from finance toward entrepreneurship


• 17:53 The founding team


• 26:08 About Nanograb


• 31:31 Chris’ YC experience


• 38:12 Chris’ view on hiring


• 42:04 Advice to 20-year old self

-

☕️ References:

• Y Combinator: a startup accelerator that invests in a wide range of startups.


• AlphaFold: an artificial intelligence program developed by DeepMind, a subsidiary of Alphabet, which performs predictions of protein structure. Having revealed millions of intricate 3D protein structures, it is helping scientists understand how all of life's molecules interact.

-

☕️ About Us:

• Victoria: Management Consultant | VC | Entrepreneur | Imperial College London Chemistry alum | 🔗 LinkedIn


• Jecci: Documentary Filmmaker | Cambridge MPhil Social Anthropology alum | 🔗 LinkedIn

-

☕️ Production Team:

Host: Victoria

Audio Editing: Jeff

-

☕️ Disclaimer:

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any fund.